Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Taysha Gene Therapies, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 5.07 · gapped above the open, then crossed back over prior close. High/low 5.11 at 2:30 pm ET, 4.91 at 9:30 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In August 2020, we entered into the Abeona CLN1 Agreement with Abeona.”
FILING10-K0001193125-26-115202cik 0001806310
“In connection with the UT Southwestern Agreement, we obtained an exclusive, worldwide, royalty-free license under certain patent rights of UT Southwestern and a non-exclusive, worldwide, royalty-free license under certain know-how of UT Southwestern, in each case to make, have made, use, sell, offer for sale and import licensed products for use in certain specified indications.”
FILING10-K0001193125-26-115202cik 0001806310
“In connection with the UT Southwestern Agreement, we issued to UT Southwestern 2,179,000 shares of our common stock.”
FILING10-K0001193125-26-115202cik 0001806310
“Under the Abeona Rett Agreement, we also sub-license from the University of North Carolina at Chapel Hill 9 pending patent applications worldwide directed to feedback-enabled synthetic genes that inhibit MECP2 expression and use of these synthetic genes for treating Rett Syndrome.”
FILING10-K0001193125-26-115202cik 0001806310
“On August 7, 2025, or the Trinity Refinance Date, we entered into a Loan and Security Agreement, or the 2025 Trinity Term Loan Agreement, by and among us, the lenders party thereto from time to time, or the 2025 Trinity Lenders, and Trinity Capital Inc., as administrative agent and collateral agent for the 2025 Trinity Lenders, or Trinity.”
FILING10-K0001193125-26-115202cik 0001806310
“In connection with the Abeona CLN1 Agreement, we obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the University of North Carolina at Chapel Hill and Abeona to research, develop, manufacture, have manufactured, use, and commercialize licensed products for gene therapy for the prevention, treatment, or diagnosis of CLN1 Disease (one of the forms of Batten disease) in humans.”
FILING10-K0001193125-26-115202cik 0001806310
“On November 4, 2025, we and Leerink Partners LLC entered into an Amendment to the Sales Agreement pursuant to which the Sales Agreement was terminated solely with respect to Leerink Partners LLC.”
FILING10-K0001193125-26-115202cik 0001806310
“SSI provides certain consulting services to us.”
FILING10-K0001193125-26-115202cik 0001806310
“On October 21, 2022, or the Effective Date, we entered into the Option Agreement with Astellas.”
FILING10-K0001193125-26-115202cik 0001806310
“During the year ended December 31, 2025, SSI exercised all 316,667 vested and outstanding Warrant Shares.”
FILING10-K0001193125-26-115202cik 0001806310
“To date, our manufacturing partners have met our manufacturing requirements and quality standards for our program materials, and we expect that these organizations, primarily Catalent, will be capable of providing sufficient quantities of our program materials to meet anticipated clinical trial scale demands.”
FILING10-K0001193125-26-115202cik 0001806310
“In November 2019, we entered into the UT Southwestern Agreement with The Board of Regents of the University of Texas System on behalf of UT Southwestern, as amended in April 2020.”
FILING10-K0001193125-26-115202cik 0001806310
Watchlist prices, news filtered to it, and its next report on your desk.
Taysha Gene Therapies, Inc. has 10 disclosed suppliers and 2 disclosed customers. Each one is named in an SEC filing, either Taysha Gene Therapies, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
TSHA (Taysha Gene Therapies, Inc.) has 10 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ABEO +0.83%, in healthcare.